Loading...
•
Mar 31, 2021
BioCryst Q1 2021 Earnings Report
BioCryst announced financial results for the first quarter ended March 31, 2021, and provided a corporate update.
Key Takeaways
BioCryst's Q1 2021 total revenues were $19.1 million, primarily driven by $10.9 million in ORLADEYO net revenue. The company's net loss was $64.3 million, or $0.36 per share. Cash, cash equivalents, restricted cash and investments totaled $244.4 million at March 31, 2021.
ORLADEYO net revenue reached $10.9 million in Q1 2021.
ORLADEYO is now approved in the U.S., Japan, and EU.
Agreement reached with FDA on hemoglobin change as primary endpoint for pivotal PNH trials of oral BCX9930.
PNH trials of oral BCX9930 are set to begin in the second half of 2021.
Forward Guidance
BioCryst is not providing specific revenue or operating expense guidance for the launch period of ORLADEYO. The company believes its current cash runway extends into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...